Why the market will watch Calluna Pharma’s CAL101 more closely after AURORA enrollment ends ahead of plan
Calluna Pharma finished Phase 2 AURORA enrollment early for CAL101 in IPF. Read what this means for fibrosis competition and Q1 2027 data.
Why Baseimmune’s IPF entry challenges a decade of single-target failure in pulmonary fibrosis
Baseimmune launches IPF pipeline using computational multi-pathway antigen design. Preclinical readouts due 2026-27. Discover what this means for fibrosis drug development.
United Therapeutics targets 2026 FDA submission for Tyvaso IPF indication after TETON-2 success
TETON-2 phase 3 data show nebulized treprostinil slows IPF lung decline and cuts clinical worsening risk. Analysis of what the NEJM results mean.
JAMA validates nalbuphine ER’s efficacy in IPF chronic cough as Trevi eyes next steps
Trevi’s IPF cough trial results for nalbuphine ER get published in JAMA. Find out what this means for future approvals and respiratory drug development.